Bacterial Pneumonia - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2016" report to their offering.

Bacterial Pneumonia Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung's air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris.

This often impairs the body's ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

Bacterial Pneumonia pipeline therapeutics constitutes close to 83 molecules. Out of which approximately 70 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 7, 11, 1, 31, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 5 molecules, respectively.

Our latest report Bacterial Pneumonia - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

Companies Mentioned

  • Abera Bioscience AB
  • Actelion Ltd
  • Alvogen Korea Co., Ltd.
  • Aridis Pharmaceuticals LLC
  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraFect Corporation
  • Daiichi Sankyo Company, Limited
  • Double Bond Pharmaceutical International AB
  • Emergent BioSolutions Inc.
  • FluGen, Inc.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • ImmunoBiology Limited
  • Indian Immunologicals Limited
  • Integrated BioTherapeutics, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • LG Life Science LTD.
  • Liquidia Technologies, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Noxxon Pharma AG
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • SK Chemicals Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Valneva SE
  • Vaxxilon AG
  • Virometix AG
  • Walvax Biotechnology Co., Ltd.
  • Wellstat Vaccines, LLC
  • Wockhardt Limited

For more information visit http://www.researchandmarkets.com/research/s3rw7z/bacterial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory Drugs, Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory Drugs, Infectious Diseases Drugs